Mathieu C, et al. - In those with ineffectively controlled type 1 diabetes (HbA1c ≥7.7 to ≤11.0% [≥61 to ≤97 mmol/mol]) who received dapagliflozin as an adjunct to adjustable insulin, researchers evaluated continuous glucose monitoring (CGM) in. this pooled analysis. They obtained CGM data from two 24-week, double-blind, randomized, phase 3 studies: Dapagliflozin Evaluation in Patients with Inadequately Controlled Type 1 Diabetes (DEPICT-1 and DEPICT-2). The study sample consisted of 1,591 patients receiving dapagliflozin 5 mg (n=530), dapagliflozin 10 mg (n=529), or placebo (n=532). Investigators observed no marked differences at week 24 between dapagliflozin 5 or 10 mg and placebo in the percentage of glucose values ≤3.9 mmol/L (≤70 mg/dL) or ≤3.0 mmol/L (≤54 mg/dL) over 24 hours, or in nocturnal glucose values ≤3.9 mmol/L (≤70 mg/dL). In patients with type 1 diabetes, the time in range, mean glucose, and glycemic variability with dapagliflozin treatment over 24 weeks improved without increasing the time spent in the range signifying hypoglycemia.